MADRIGAL PHARMACEUTICALS, INC. MDGL Income Statement

Madrigal pharmaceuticals, inc. (MDGL)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Sep'10	Jun'10
License and milestone revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6,731	4,572	4,572	0	0	0
Cost sharing reimbursements, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Total collaboration revenues
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6,731	6,812	9,029	0	0	0
Grant revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	147	268	789	1,000	0	0	0	-	-	-
Total revenues
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	147	3,570	5,234	6,588	7,584	7,544	9,240	0	0	0
Operating expenses:
Research and development
93,351	72,324	56,285	43,049	32,564	25,389	23,030	23,501	25,208	24,390	23,401	24,525	19,797	15,933	17,656	10,532	24,821	40,487	48,894	64,420	66,804	68,205	72,533	73,948	73,063	71,860	66,230	60,350	53,726	49,412	45,920	44,928	44,093	41,463	41,627	40,564	0	0	0
General and administrative
21,507	22,648	23,187	23,561	19,168	15,293	12,109	8,942	7,848	7,672	7,505	11,835	10,763	9,290	10,192	4,104	6,680	10,608	11,715	14,759	14,572	15,746	14,968	15,898	17,145	15,699	15,588	14,213	12,908	11,676	11,127	11,462	11,526	11,553	11,341	10,926	0	0	0
Total operating expenses
114,858	94,972	79,472	66,610	51,732	40,682	35,139	32,443	33,056	32,062	30,906	36,360	30,560	25,223	27,848	14,637	31,502	51,096	60,610	79,179	81,376	83,951	87,501	89,846	90,208	87,559	81,818	74,563	66,634	61,088	57,047	56,390	55,619	53,016	52,968	51,490	0	0	0
Loss from operations
-114,858	-94,972	-79,472	-66,610	-51,732	-40,682	-35,139	-32,443	-33,056	-32,062	-30,906	-36,360	-30,560	-25,223	-27,848	-14,637	-31,502	-51,096	-60,610	-79,179	-81,376	-83,951	-87,501	-89,846	-90,208	-87,559	-81,818	-74,563	-66,634	-60,941	-53,477	-51,156	-49,031	-45,432	-45,424	-42,250	0	0	0
Interest income (expense), net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,746	-2,048	-1,646	-1,935	-2,210	-2,470	-2,674	-2,813	-2,633	-2,335	-2,071	-1,833	-1,849	-1,933	-1,992	-1,999	-1,948	-1,475	-989	0	0	0
Interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	1,213	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest income
9,855	11,024	0	0	0	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other income
-	-	-	-	-	-	-	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-104,968	-83,948	-67,683	-54,766	-41,527	-32,811	-29,781	-29,632	-31,519	-31,154	-30,458	-36,144	-30,674	-26,388	-29,175	-16,925	-33,848	-52,842	-62,658	-80,825	-83,311	-86,161	-89,971	-92,520	-93,021	-90,192	-84,153	-76,634	-68,467	-62,790	-55,410	-53,148	-51,030	-47,380	-46,899	-43,239	0	0	0
Net loss per common share:
Basic and diluted net loss per common share (in dollars per share)
-2.34	-1.80	-1.39	-1.28	-0.98	-0.75	-0.56	-0.45	-0.45	-0.67	-0.68	-0.69	-0.50	22.57	-1.59	-16.33	-9.72	-0.08	-10.46	-0.15	-0.19	-0.19	-0.19	-0.24	-0.28	-0.31	-0.33	-0.33	-0.30	-0.29	-0.25	-0.25	-0.27	-0.22	-0.26	-0.26	-0.27	-0.25	-0.22
Basic and diluted weighted average number of common shares outstanding
15,429	15,429	15,415	15,368	15,364	15,348	15,307	14,383	14,127	12,597	12,378	12,039	11,955	11,619	8,847	176	176	137,336	172	132,295	108,376	108,366	105,774	94,046	85,438	76,769	69,047	69,034	68,991	62,966	60,661	57,650	56,366	49,426	49,403	47,845	42,008	-	-
Basic weighted average number of common shares outstanding (in shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	40,382	40,342
Diluted weighted average number of common shares outstanding (in shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	40,382	40,342